anti-CD3/anti-CD20 bispecific T-cell engager (Rinat-Pfizer)

N/A

Report date: 2026/03/19 16:57:16

Base Information

Drug Nameanti-CD3/anti-CD20 bispecific T-cell engager (Rinat-Pfizer)

Drug Alias Nameanti-CD20/anti-CD3 bispecific antibody (Rinat-Pfizer)

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers

Mechanisms of ActionT cell surface glycoprotein CD3 modulatorsB-lymphocyte antigen CD20 modulators

TargetsB-lymphocyte antigen CD20T cell surface glycoprotein CD3

Therapy Area/IndicationsNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPending (Preclinical)

Highest Status in ChinaN/A

Originator CompaniesRinat-Pfizer Inc

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesRinat-Pfizer Inc

Active IndicationsN/A

Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A